Zhou, Zifan
Urman, Robert
Gill, Karminder
Park, Andrew S.
Vuvu, Fiston
Patel, Leah B.
Lu, Jingsong
Wade, Rolin L.
Frerichs, Lindsay
Bensink, Mark E.
Funding for this research was provided by:
Amgen
Article History
Received: 15 September 2023
Accepted: 10 October 2023
First Online: 9 November 2023
Declarations
:
: Not applicable. Study utilizes open-source US pharmacy (LRx) and medical (Dx) claims data.
: Not applicable. Study utilizes open-source US pharmacy (LRx) and medical (Dx) claims data.
: Z.Z., J.L., and R.L.W. are/were employees of IQVIA, which received funding from Amgen to conduct the research, at the time of the study. R.U., K.G., A.S.P., F.V., and L.B.P. are/were employees of Amgen at the time of the study. Z.Z., R.U., K.G., F.V., and L.B.P. own stock in Amgen. L.F. has received compensation for serving as a consultant for AbbVie. She has received CME honoraria from the American Academy of Neurology, BrainWeek, and Southern Headache Society. M.E.B., as the managing director of Benofit Consulting, has received compensation for serving as a consultant for Amgen and Travere Therapeutics.